Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the age-related eye disease study

Ophthalmology

Volumn 122, Issue 1, 2015, Pages 162-169

  Awh, Carl C ^a   Hawken, Steven ^b   Zanke, Brent W ^b,c  

^a Tennessee Retina   (United States)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c Arctic Group of Companies   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; COMPLEMENT FACTOR H; COPPER; DNA; PLACEBO; ZINC; ZINC OXIDE; ARMS2 PROTEIN, HUMAN; COMPLEMENT FACTOR H, HUMAN; PROTEIN; ZINC DERIVATIVE;

AGE RELATED MACULAR DEGENERATION; AGE RELATED MACULOPATHY SUSCEPTIBILITY 2 RISK ALLELE; AGED; ALLELE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; DISEASE COURSE; DRUSEN; GENE NUMBER; GENETIC RISK; GENOTYPE; GEOGRAPHIC ATROPHY; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL IMPAIRMENT; ADULT; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPING TECHNIQUE; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; ANTIOXIDANTS; ASCORBIC ACID; BETA CAROTENE; COMPLEMENT FACTOR H; DRUG THERAPY, COMBINATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEINS; RISK FACTORS; VITAMIN E; ZINC COMPOUNDS;

EID: 84920738808     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.07.049     Document Type: Article

References (20)

1. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol 2001;119:1439-52.
2. van Leeuwen R, Boekhoorn S, Vingerling JR, et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005;294:3101-7.
3. Awh CC, Lane AM, Hawken S, et al. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 2013;120:2317-23.
4. Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 2008;115:1019-25.
5. Seddon JM, Reynolds R, Yu Y, et al. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 2011;118:2203-11.
6. Awh CC, Lane AM, Hawken S, et al. In reply to: Schwartz SG. Re: Awh et al: CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 2014:121e39.
7. Chew EY, Klein ML, Clemons TE, et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology 2014 Jun 26. pii: S0161e6420(14)00428-X. doi: 10.1016/j.ophtha.2014.05.008. [Epub ahead of print]
8. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of highdose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36.
9. Li M, Tmaca-Sonmez P, Othman M, et al. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet 2006;38:1049-54.
10. Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491:56-65.
11. Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 2006;38:1055-9.
12. Fritsche LG, Loenhardt T, Janssen A, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet 2008;40:892-6.
13. International HapMap C, Frazer KA, Ballinger DG, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851-61.
14. Ho L, van Leeuwen R, Witteman JC, et al. Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and omega-3 fatty acids: the Rotterdam study. Arch Ophthalmol 2011;129:758-66.
15. Lengyel I, Peto T. Cure or cause: the opposing roles for zinc in age-related macular degeneration. Expert Rev Ophthal 2008;3: 1-4.
16. Lengyel I, Flinn JM, Peto T, et al. High concentration of zinc in sub-retinal pigment epithelial deposits. Exp Eye Res 2007;84:772-80.
17. Nan R, Gor J, Lengyel I, Perkins SJ. Uncontrolled zinc- and copper-induced oligomerisation of the human complement regulator factor H and its possible implications for function and disease. J Mol Biol 2008;384:1341-52.
18. Nan R, Farabella I, Schumacher FF, et al. Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration. J Mol Biol 2011;408:714-35.
19. Yang J, Li Y, Chan L, et al. Validation of genome-wide association study (GWAS)-identified disease risk alleles with patientspecific stem cell lines. Hum Mol Genet 2014;23:3445-55.
20. Imamura Y, Noda S, Hashizume K, et al. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. Proc Natl Acad Sci U S A 2006;103:11282-7.